We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.
- Authors
Ceriello, Antonio; Rodbard, Helena W.; Battelino, Tadej; Brosius, Frank; Cosentino, Francesco; Green, Jennifer; Ji, Linong; Kellerer, Monika; Koob, Susan; Kosiborod, Mikhail; Lalic, Nebojsa; Marx, Nikolaus; Nedungadi, T. Prashant; Parkin, Christopher G.; Rydén, Lars; Sheu, Wayne Huey-Herng; Standl, Eberhard; Vandvik, Per Olav; Schnell, Oliver
- Abstract
In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.
- Subjects
TYPE 2 diabetes; MINERALOCORTICOID receptors; GLUCAGON-like peptide-1 receptor; DIABETES; GLUCAGON-like peptide-1 agonists; HYPERGLYCEMIA
- Publication
Cardiovascular Diabetology, 2023, Vol 22, Issue 1, p1
- ISSN
1475-2840
- Publication type
Article
- DOI
10.1186/s12933-023-01993-3